Figure 3.

Aca exerts potent anti-leukemic effect in MDS and AML bone marrow cell ex vivo. Bone marrow cells from Aza refractory MDS/AML patients (10⁶/mL) were incubated for 24 h with 1 µM Aza or different concentration of Aca. Loss of cell proliferation was assessed using the XTT assay as described in Figure 1. Each assay was performed in quadruplicate. The mean values for each MDS patient and each AML patients are shown on Figure 3 (A) and (B) respectively. * p < 0.05, *** p < 0.001, ns: not significant. The bone marrow cells from two patients (in red) were slightly sensitive to Aza.